Medpace Holdings Inc (NASDAQ:MEDP) Shares Sold by Strs Ohio

Share on StockTwits

Strs Ohio reduced its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,700 shares of the company’s stock after selling 400 shares during the quarter. Strs Ohio’s holdings in Medpace were worth $1,027,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc grew its holdings in shares of Medpace by 572.4% in the fourth quarter. Legal & General Group Plc now owns 23,102 shares of the company’s stock worth $1,201,000 after purchasing an additional 19,666 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Medpace by 41.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 506,896 shares of the company’s stock worth $26,829,000 after purchasing an additional 147,472 shares during the last quarter. Norges Bank bought a new position in shares of Medpace in the fourth quarter worth approximately $8,004,000. Geode Capital Management LLC grew its holdings in shares of Medpace by 5.4% in the fourth quarter. Geode Capital Management LLC now owns 320,938 shares of the company’s stock worth $16,986,000 after purchasing an additional 16,521 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in shares of Medpace by 401.7% in the first quarter. State of Alaska Department of Revenue now owns 8,780 shares of the company’s stock worth $517,000 after purchasing an additional 7,030 shares during the last quarter. 76.98% of the stock is owned by institutional investors and hedge funds.

NASDAQ:MEDP opened at $79.50 on Wednesday. The company has a market capitalization of $2.84 billion, a PE ratio of 30.69, a P/E/G ratio of 2.16 and a beta of 1.57. The firm has a fifty day moving average of $67.87. Medpace Holdings Inc has a twelve month low of $45.88 and a twelve month high of $80.65. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, July 29th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.18. The business had revenue of $214.10 million for the quarter, compared to analysts’ expectations of $200.99 million. Medpace had a net margin of 11.28% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.61 earnings per share. Analysts predict that Medpace Holdings Inc will post 2.91 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the stock. TheStreet upgraded shares of Medpace from a “c” rating to a “b-” rating in a report on Thursday, June 6th. ValuEngine upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. SunTrust Banks lifted their price target on shares of Medpace to $85.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Credit Suisse Group lifted their price target on shares of Medpace from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Tuesday, July 30th. Finally, Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Medpace currently has a consensus rating of “Buy” and a consensus target price of $73.75.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

See Also: Commodities

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Oxford Square Capital Corp  Announces $0.07 Monthly Dividend
Oxford Square Capital Corp Announces $0.07 Monthly Dividend
Oxford Lane Capital Corp Announces Monthly Dividend of $0.14
Oxford Lane Capital Corp Announces Monthly Dividend of $0.14
Canadian Utilities Limited  Director Sells C$74,228.00 in Stock
Canadian Utilities Limited Director Sells C$74,228.00 in Stock
Insider Selling: Diodes Incorporated  VP Sells $70,469.01 in Stock
Insider Selling: Diodes Incorporated VP Sells $70,469.01 in Stock
General Mills  Posts  Earnings Results, Beats Expectations By $0.02 EPS
General Mills Posts Earnings Results, Beats Expectations By $0.02 EPS
ETF Managers Group LLC Reduces Stock Position in iShares Barclays 1-3 Year Treasry Bnd Fd
ETF Managers Group LLC Reduces Stock Position in iShares Barclays 1-3 Year Treasry Bnd Fd


© 2006-2019 Ticker Report